Navigation Links
YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS
Date:9/23/2007

n February 2006, the acquisition of Eximias Pharmaceutical Corporation in May 2006, and the licensing payment from Daiichi Pharmaceutical Co., Ltd.

Total operating expenditures for the fiscal year ended June 30, 2007 were $37.6 million compared to $28.1 million for the fiscal year ended June 30, 2006. Total operating expenditures for the fourth quarter ended June 30, 2007 were $6.5 million compared to $9.3 million for the same quarter in 2006.

General and administrative expenses decreased to $7.0 million in fiscal 2007 compared to $8.0 million in fiscal 2006. This was mainly due to a decrease in stock based compensation expense of $872,000.

Licensing and product development expenses increased by $8.6 million from $20.2 million in fiscal 2006 to $28.8 million in fiscal 2007. Costs associated with development activities for nimotuzumab increased to $5.9 million compared to $4.8 million in fiscal 2006 as a result of commissions and consulting fees associated with obtaining the licensing agreement with Daiichi-Sankyo and additional costs relating to pre-clinical and clinical studies. Costs associated with development activities for AeroLEF(TM) decreased to $2.9 million in fiscal 2007 compared to $4.1 million in fiscal 2006, mainly due to decreased costs related to the Phase II trial in acute pain. Costs related to development activities for tesmilifene for fiscal 2007 decreased to $7.5 million in fiscal 2007 compared to $11.3 million in fiscal 2006, mainly due to the closing down the Phase III trial and the settlement of holdback amounts from the original contract for the trial.

Employee compensation relating to licensing and product development increased by $5.2 million for fiscal 2007 compared to fiscal 2006. The increase is partly attributed to salaries and bonuses related to employees who joined YM as part of the Eximias acquisition in May 2006. Also, during the year the Company incurred expenses with respect to the termination of certain US
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Knowledgent , the data and analytics ... advanced analytics utilizing data lakes in the healthcare industry. , As the Internet of ... of data over the last few years as more entities become technology enabled through ...
(Date:9/1/2015)... ... 2015 , ... Industry leader iLab Solutions recently announced Gerard ... position, Gibbs will lead iLab’s business operations in the region, with an emphasis ... not only introducing iLab to potential partners but support and management of accounts ...
(Date:9/1/2015)... CA (PRWEB) , ... September 01, 2015 , ... ... and colleagues from University of California Los Angeles, Boston University School of Medicine, ... Prevention appears in PLOS One, the world’s first multidisciplinary Open Access journal. ...
(Date:9/1/2015)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces ... of Directors as a Non-Executive Director. Sara will also be ... the Shire Board. Both appointments will be effective as of ... President and Chief Executive Officer of Dun & Bradstreet, Inc. ... D&B, she helped drive the transformation of the company from ...
Breaking Biology Technology:New White Paper Explores Data Lake Opportunities in the Healthcare Industry 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3Shire Appoints Sara Mathew to Board of Directors 2
... - AEterna Zentaris Inc.,(NASDAQ: AEZS ; TSX: ... and oncology, today reported the completion of patient,recruitment ... Phase 3 program,in benign prostatic hyperplasia (BPH), a ... candidate, cetrorelix. The study,involves approximately 600 patients primarily ...
... FRESNO, Calif., April 15 Chairman & CEO, Paul ... agribusiness company, Dr.,Mark E. Whitacre has risen fast at ... operating officer and president of operations.",Now Cypress and Whitacre ... in order to get Americans -- and people around ...
... Clinical Trials ... Session -, SAN ... today announced that data from an ongoing,Phase 1-2 clinical trial showed that ... prostate specific,antigen (PSA), a marker of tumor growth, in the lowest expanded ...
Cached Biology Technology:AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia 4Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R) 2Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R) 3Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients 2Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients 3
(Date:8/12/2015)... JOSE, Calif. , Aug. 12, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... recently announced Match-in-Sensor solution, have officially been named ... Alliance. As part of the certification, Synaptics, Natural ... FIDO 1.0 Universal Authentication Framework (UAF) standard and ...
(Date:8/10/2015)... Germany , August 10, 2015 ... leader in Eye Tracking Technology for more than two ... Tracking Platform for integration into all consumer display formats. ... for seamless integration of eye tracking into consumer tablets, ... augmented reality smart glasses. Omnivision,s leading sensor technology contributes ...
(Date:8/6/2015)... Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon Valley ... Crossmatch is a world leader in multi-factor identity ... are helping federal agencies and commercial organizations achieve ... "The vast majority of network breaches ...
Breaking Biology News(10 mins):Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2
... others. That popular phrase on a T-shirt is ... education these days, as experts in a variety of ... society,s biggest challenges, from a warming planet to cancer. ... institutions collaborate? How do they work together to incorporate ...
... has fewer invasive woody plants than the United States, ... is high, according to an article in the May ... University of Zurich in Switzerland, and Bo Li, of ... with alien plant species invasions and compared the history ...
... have discovered how some bacteria can survive antibiotic treatment ... drugs. The findings, published in the April 24 issue ... effective antibiotics to treat a variety of infections. ... can turn on the genes that protect them from ...
Cached Biology News:Biologists are from Mars, chemists are from Venus? 2Biologists are from Mars, chemists are from Venus? 3Woody and aquatic plants pose greatest invasive threat to China 2UIC scientists discover how some bacteria survive antibiotics 2
... sets a new standard for high performance ... new design in instrumentation, this easy-to-use benchtop ... The BD FACSAria instrument is the first ... flow cell. This new flow cell ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Mouse monoclonal antibody raised against a full length recombinant LDB3. NCBI Entrez Gene ID = LDB3...
Biology Products: